At the Bedside: Adoptive cell therapy for melanoma-clinical development

Journal of Leukocyte Biology

Volumn 95, Issue 6, 2014, Pages 875-882

  Weber, Jeffrey S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

IL 2; Immunotherapy; Lymphoid depletion; T cell; T cell receptor

Indexed keywords

INTERLEUKIN 2;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CD4+ T LYMPHOCYTE; CELL THERAPY; DRUG MEGADOSE; GENE TRANSFER; LYMPHOCYTE CLONE; LYMPHOCYTE DEPLETION; LYMPHOID CELL; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

IL-2; IMMUNOTHERAPY; LYMPHOID DEPLETION; T CELL; T CELL RECEPTOR;

CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; RECEPTORS, ANTIGEN, T-CELL;

EID: 84901706683     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0513293     Document Type: Article

References (46)

1. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492.
2. Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., Rosenberg, S. A. (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58, 2764-2772.
3. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N. Engl. J. Med. 315, 889-897.
4. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85, 622-632.
5. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon Topalian, D. S., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676-1680.
6. Griffith, K. D., Read, E. J., Carrasquillo, J. A., Carter, C. S., Yang, J. C., Fisher, B., Aebersold, P., Packard, B. S., Yu, M. Y., Rosenberg, S. A. (1989) In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J. Natl. Cancer Inst. 81, 1709-1716.
7. Fisher, B., Packard, B. S., Read, E. J., Carrasquillo, J. A., Carter, C. S., Topalian, S. L., Yang, J. C., Yolles, P., Larson, S. M., Rosenberg, S. A. (1989) Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7, 250-261.
8. Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., et al. (1990) Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570-578.
9. Schwartzentruber, D. J., Solomon, D., Rosenberg, S. A., Topalian, S. L. (1992) Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J. Immunother. 12, 1-12.
10. Aebersold, P., Hyatt, C., Johnson, S., Hines, K., Korcak, L., Sanders, M., Lotze, M., Topalian, S., Yang, J., Rosenberg, S. A. (1991) Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J. Natl. Cancer Inst. 83, 932-937.
11. Pockaj, B. A., Sherry, R. M., Wei, J. P., Yannelli, J. R., Carter, C. S., Leitman, S. F., Carasquillo, J. A., Steinberg, S. M, Rosenberg, S. A., Yang, J. C. (1994) Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73, 1731-1737.
12. Schwartzentruber, D. J., Hom, S. S., Dadmarz, R., White, D. E. (1994) In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol.12, 1475-1483.
13. Zhou, J., Shen, X., Huang, J., Hodes, R. J., Rosenberg, S. A., Robbins, P. F. (2005) Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046-7052.
14. Huang, J., Khong, H. T., Dudley, M. E., El-Gamil, M., Li, Y. F., Rosenberg, S. A. Robbins, P. F. (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28, 258-267.
15. Joseph, R. W., Peddareddigari, V. R., Liu, P., Miller, P. W., Overwijk, W. W., Bekele, N. B., Ross, M. I., Lee, J. E., Gershenwald, J. E., Lucci, A., et al. (2011) Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin. Cancer Res. 17, 4882-4891.
16. Radvanyi, L. G., Bernatchez, C., Zhang, M., Fox, P. S., Miller, P., Chacon, J., Wu, R., Lizee, G., Mahoney, S., Alvarado, G., et al. (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18, 6758-6770.
17. Friedman, K. M., Prieto, P. A., Devillier, L. E., Gross, C. A., Yang, J. C., Wunderlich, J. R., Rosenberg, S. A., Dudley, M. E. (2012) Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J. Immunother. 35, 400-408.
18. Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes. Science 298, 850-854.
19. Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J., Rosenberg, S. A. (2003) Generation of infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 328-342.
20. Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. C., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 3, 2346-2357.
21. Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239.
22. Muranski, P., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R., Restifo, N. P. (2006) Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat. Clin. Pract. Oncol. 3, 668-681.
23. Wallen, H., Thompson, J. A., Reilly, J. Z., Rodmyre, R. M., Cao, J., Yee, C. (2009) Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 4, e4749.
24. Rosenberg, S. A., Restifo, N. P, Yang, J. C., Morgan, R. A., Dudley, M. E. (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308.
25. Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557.
26. Pilon-Thomas, S., Kuhn, L., Ellwanger, S., Janssen, W., Royster, E., Marzban, S., Kudchadkar, R., Zager, J., Gibney, G., Sondak, V. K., Weber, J., Mulé, J. J., Sarnaik, A. A. (2012) Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J. Immunother. 35, 615-620.
27. Ullenhag, G. J., Sadeghi, A. M., Carlsson, B., Ahlström, H., Mosavi, F., Wagenius, G., Tötterman, T. H. (2012) Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. Cancer Immunol. Immunother. 61, 725-732.
28. Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., Shalmon, B., Hardan, I., Catane, R., Markel, G., Apter, S., Ben-Nun, A., Kuchuk, I., Shimoni, A., Nagler, A., Schachter, J. (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646-2655.
29. Tran, K. Q., Zhou, J., Durflinger, K. H., Langhan, M. M., Shelton, T. E., Wunderlich, J. R., Robbins, P. F., Rosenberg, S. A., Dudley, M. E. (2008) Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 31, 742-751.
30. Dudley, M. E., Gross, C. A., Langhan, M. M., Garcia, M. R., Sherry, R. M., Yang, J. C., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., Restifo, N. P., Wunderlich, J. R., Prieto, P. A., Hong, J. J., Langan, R. C., Zlott, D. A., Morton, K. E., White, D. E., Laurencot, C. M., Rosenberg, S. A. (2010) CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 16, 6122-6131.
31. Ellebaek, E, Iversen, T. Z., Junker, N., Donia, M., Engell-Noerregaard, L., Met, Ö., Hölmich, L. R., Andersen, R. S., Hadrup, S. R., Andersen, M. H., Thor Straten, P., Svane, I. M. (2012) Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients. J. Transl. Med. 21, 169-176.
32. Somerville, R. P., Devillier, L., Parkhurst, M. R., Rosenberg, S. A., Dudley, M. (2012) Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. J. Transl. Med. 4, 69-75.
33. Jin, J., Sabatino, M., Somerville, R., Wilson, J., Dudley, M. E., Stroncek, D. F., Rosenberg, S. A. (2012) Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J. Immunother. 35, 283-292.
34. Hong, J. J., Rosenberg, S. A., Dudley, M. E., Yang, J. C., White, D. E., Butman, J. A., Sherry, R. M. (2006) Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16, 4892-4898.
35. Powell D. J., Jr., Dudley, M. E., Hogan, K. A., Wunderlich, J. R., Rosenberg, S. A. (2006) Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J. Immunol. 177, 6527-6539.
36. Smith, F. O., Klapper, J. A., Wunderlich, J. R., Rosenberg, S. A., Dudley, M. E. (2009) Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. J. Immunother. 32, 870-874.
37. Dudley, M. E., Wunderlich, J., Nishimura, M. I., Yu, D., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Sherry, R., Leitman, S. F., Rosenberg, S. A. (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24, 363-373.
38. Prieto, P. A., Durflinger, K. H., Wunderlich, J. R., Rosenberg, S. A., Dudley, M. E. (2010) Enrichment of CD8+ cells from melanoma tumorinfiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J. Immunother. 33, 547-556.
39. Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., Greenberg, P. D. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99, 16168-16173.
40. Chapuis, A. G., Thompson, J. A., Margolin, K. A., Rodmyre, R., Lai, I. P., Dowdy, K., Farrar, E. A., Bhatia, S., Sabath, D. E., Cao, J., Li, Y., Yee, C. (2012) Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc. Natl. Acad. Sci. USA 109, 4592-4597.
41. Inozume, T., Hanada, K., Wang, Q. J., Ahmadzadeh, M., Wunderlich, J. R., Rosenberg, S. A., Yang, J. C. (2010) Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J. Immunother. 33, 956-964.
42. Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., Yee, C. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703.
43. Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., Zheng, Z., Nahvi, A., et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
44. Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546.
45. Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924.
46. Parkhurst, M. R., Riley, J. P., Dudley, M. E., Rosenberg, S. A. (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17, 6287-6297.